2025
24R,25(OH)2D3 regulates tumorigenesis in estrogen sensitive laryngeal cancer cells via membrane‐associated receptor complexes in ER+ and ER− cells
Dennis C, Cohen D, Debnath K, Schwartz N, Lodato B, Dillon J, Batool T, Halquist M, Ghosh P, Schwartz Z, Boyan B. 24R,25(OH)2D3 regulates tumorigenesis in estrogen sensitive laryngeal cancer cells via membrane‐associated receptor complexes in ER+ and ER− cells. International Journal Of Cancer 2025 PMID: 40920031, DOI: 10.1002/ijc.70141.Peer-Reviewed Original ResearchProtein disulfide-isomerase A3UM-SCC-11A cellsER- cellsMembrane-associated receptor complexDownstream signaling cascadesTumorigenesis in vivoMessenger signaling pathwaysLaryngeal cancer cellsAnti-tumorigenic effectsSignaling cascadesLaryngeal cancer patientsSignaling pathwayDNA synthesisPI3KER+ cellsER- tumorsER+ tumorsCancer cellsP53 productCell linesEstrogen-dependentReceptor complexTumor cellsCancer patientsCYP24A1 proteinAssociation between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets
Robinson T, Liveringhouse C, Wilson C, Friedman S, Nakashima J, Mills M, Purcell J, Figura N, Dongliang D, Thapa R, Welsh E, Ahmed K, Grass G, Fridley B, Diaz R. Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets. Breast Cancer Research 2025, 27: 77. PMID: 40361136, PMCID: PMC12070507, DOI: 10.1186/s13058-025-01987-x.Peer-Reviewed Original ResearchConceptsAssociated with locoregional recurrenceER + tumorsLocoregional recurrenceER- tumorsT cell activationAntigen presentationBreast cancerDiagnosed non-metastatic breast cancerEstrogen receptor negative breast cancerHazard ratioMHC-IIReceptor negative breast cancerUp-regulatedMHC-II signalingInvasive breast tumorsMedian Follow-UpMHC-II-mediated antigen presentationExogenous antigen presentationNon-metastatic breast cancerNegative breast cancerUnivariate Cox modelDR genesDown-regulationAssociated with proliferationMethodsTranscriptomic profiles
2020
Association between low estrogen receptor positive breast cancer and staining performance
Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. Npj Breast Cancer 2020, 6: 5. PMID: 32047851, PMCID: PMC7002746, DOI: 10.1038/s41523-020-0146-2.Peer-Reviewed Original ResearchER expressionER- tumorsBreast carcinomaTissue microarrayNormal epitheliumEstrogen receptor-positive breast cancerER casesReceptor-positive breast cancerControl patient populationER-positive tumorsEstrogen receptor expressionPositive breast cancerMean optical densityBackground epitheliumPositive tumorsControl cohortPatient populationControl tumorsReceptor expressionBenign epitheliumBreast cancerRare caseNormal ductsER stainingTumors
2010
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
Lehmann‐Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa L, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, Thé H. Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers. The Oncologist 2010, 15: 246-252. PMID: 20228131, PMCID: PMC3227956, DOI: 10.1634/theoncologist.2009-0243.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancer patientsCancer patientsDose intensificationDose intensityP53 statusAnthracycline resistanceHigh-dose cyclophosphamide administrationP53-mutant breast cancersAnthracycline-based regimensTriple-negative tumorsPretreatment tumor samplesMutant breast cancerChemotherapy regimensComplete responseER expressionCyclophosphamide administrationER- tumorsTumor responsePooled resultsBreast cancerYeast functional assayPatientsPredictive valueMultivariate analysis
2009
The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and ER-Negative Cancers.
Bianchini G, Bianchini G, Alvarez R, Qi Y, Hatzis C, Iwamoto T, Shiang C, Coutant C, Hortobagyi G, Symmans W, Pusztai L. The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and ER-Negative Cancers. Cancer Research 2009, 69: 105-105. DOI: 10.1158/0008-5472.sabcs-09-105.Peer-Reviewed Original ResearchDistant metastasis-free survivalCore needle biopsyFine-needle aspirationER- cancersPrognostic valueCancer cell linesER- tumorsB cells/plasma cellsStromal signaturesStromal genesBreast cancer stromaConsistent prognostic valueER- breast cancer cell linesReproducible prognostic markerTamoxifen-treated patientsIndependent prognostic roleER-negative cancersMetastasis-free survivalStromal gene signatureBreast cancer cell linesVariable prognostic valueCell linesFree survivalPreoperative chemotherapyUntreated patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply